Company
Every investor coverage indicates participated in a round MTAA Super raised.
Companies MTAA Super acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming MTAA Super. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A directory of fifteen Canberra investors backing deep tech, noting ACTivate Capital's fund first close, several government-backed company raises, an incubator's alumni, and one portfolio acquisition.
GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.
Also GBS Ventures·novartis.com·clinicalleader.com·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia